The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.

Fintel reports that on March 24, 2025, JP Morgan upgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) from Neutral to Overweight. Analyst Price Forecast Suggests 11.73% Upside As of ...

Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective lifted by Royal Bank of Canada from $310.00 to ...

Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target increased by Canaccord Genuity Group from $385.00 to $390.00 in a report issued on Friday,Benzinga reports. The brokerage ...

JPMorgan upgraded Alnylam (ALNY) to Overweight from Neutral with a price target of $328, up from $280. The firm increased TTR silencer ...

The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development ...

President Trump selected Susan Monarez, the acting director of the Centers for Disease Control and Prevention, for the ...

In the last week, the United States market has remained flat, yet it has achieved an 8.1% increase over the past year with earnings anticipated to grow by 14% annually in the coming years. In this ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.